2026 Summit

Course Description

Activity Dates: 10/01/2026 - 07/01/2027

The Summit is an application-based continuing pharmacy education (CPE) activity designed to advance the knowledge and improve competency of participants through the delivery of evidence-based presentations on emerging areas of practice and contemporary issues in psychiatric pharmacy. This two-day, interactive, virtual conference provides knowledge and tools to improve the comprehensive care of patients with mental health disorders. The content is valuable to all psychiatric pharmacists regardless of the practice setting.
 
An application-based CPE activity requires that participants apply the information learned. In an application-based CPE activity, the learning objectives are written at a higher level in order to assess the learners’ ability to use the information that is learned, at the expected level of practice of Board Certified Psychiatric Pharmacists. The examination for this product often features cases requiring that the participant apply the principles learned through the presentations.
 
The Summit includes:
  1. Online access to the recorded speakers' audio presentations synchronized with their slide presentations (presented live during the Virtual Summit, October 1-2 2026).
  2. For pharmacists, 10 hours of ACPE credit and 10 hours of BCPP Recertification credit achieved by successfully completing the online AAPP recertification examination.
  3. Access to the AAPP testing center with exam submission due on or before July 1, 2027. Exam extensions will not be granted after exam deadlines. In cases of personal or family illness that prevents completion of an exam, AAPP will transfer your product purchase to a comparable BCPP Recertification course after a letter documenting the unique circumstances is received by the AAPP office.

Consider making this product part of your BPS Continuing Professional Development plan! Please refer to the BPS Psychiatric Pharmacy Content Outline to see how this activity may align.

Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.

Target Audience

BCPPs desiring an evidence-based focus on emerging areas of practice and contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who learn best from didactic presentations, are auditory and visual learners, and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.

Continuing Education Credit and Disclosures

Activity Dates: 10/01/2026 - 07/01/2027
ACPE Contact Hours: 10
ACPE Numbers: TBA
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.

ACPEThe American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 10 hours of ACPE credit and 10 hours of BCPP Recertification credit by successfully completing the online examination.

The American Association of Psychiatric Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). This course is part of a 10 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.
 
AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

View planning committee disclosures

Summit Editorial Board

Jade Abudia, PharmD, BCPP
San Carlos Apache Health Corporation
Peridot, AZ
No Relevant Financial Relationships to Disclose

Dana Chiulli, PharmD, BCPP
Clinical Pharmacist Practitioner - Mental Health
VISN 06 Mental Health Clinical Resource Hub
Flower Mound, TX
No Relevant Financial Relationships to Disclose

Beth DeJongh, PharmD, BCPS, BCPP
Director of Continuing Professional Development
American Association of Psychiatric Pharmacists
Lincoln, NE
No Relevant Financial Relationships to Disclose

Traci Dutton, PharmD, BCPS, BCPP
VA Tennessee Valley Healthcare System
Clinical Pharmacy Specialist - Mental Health; Program Director - PGY2
Murfreesboro, TN
No Relevant Financial Relationships to Disclose

Megan Ehret, PharmD, MS, BCPP, FAAPP
Vice-Chair for Academic Affairs
University of Maryland, School of Pharmacy
Baltimore, MD
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Saladex Biomedical Consultant, Lexi-Comp Consultant/Reviewer
Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH

Courtney Iuppa, PharmD, BCPP
Clinical Pharmacy Manager; Residency Program Director
Center for Behavioral Medicine
Kansas City, MO
No Relevant Financial Relationships to Disclose

Jessa Koch, PharmD, BCPP
Pharmacist
Loma Linda University School of Pharmacy
Loma Linda, CA
Educational Grants, Research Grants or Contracts: NACDS, HRSA

Amber Lemons, PharmD, BCPP
Clinical Pharmacist Specialist Psychiatry
Childrens Hospital Colorado
No Relevant Financial Relationships to Disclose

Sandra Mitchell, BCPP, PharmD, FAAPP
Clinical Pharmacy Specialist – Psychiatry
VCU Health System
Richmond, VA
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Wolters Kluwer Consultant

Sarah Popish, PharmD, BCPP
VA PBM Academic Detailing Services, Program Manager
Department Of Veterans Affairs
Sarasota, FL
No Relevant Financial Relationships to Disclose

Carly Rainey, PharmD, BCPS, BCPP
Clinical Pharmacy Practitioner
Memphis VA Medical Center
Memphis, TN
No Relevant Financial Relationships to Disclose

Rebecca Reiss, PharmD, BCPP 
Behavioral Health Clinical Pharmacist Specialist
Denver Health Medical Center
Denver, CO
No Relevant Financial Relationships to Disclose

All relevant relationships have been mitigated.

View disclaimer and disclosure of off-label use

Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.

In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

View fair balance and integrity statement

It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.